Merz Therapeutics' XEOMIN (incobotulinumtoxinA) receives new therapeutic indication for the United Kingdom
Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom
Source: finanznachrichten.de